Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of autologous bone marrow mononuclear cell therapeutic angiogenesis in diabetic patients with non-revascularizable critical chronic lower limb ischemia
2008-004064-39Phase 2Completed
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Jul 2008
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous bone marrow-derived mononuclear cell in chronic limb-threatening ischemia (CLTI) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Adverse events and serious adverse events. Started Jul 2008; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
chronic limb-threatening ischemia (CLTI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-004064-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004064-39.